1. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP
- Author
-
M. Tölle, Wolfram J. Jabs, Fedai Özcan, Lucas Kühne, Jan Menne, Regina Herbst, Timm H. Westhoff, Paul T. Brinkkoetter, Sebastian A. Potthoff, Andreas Kribben, Vedat Schwenger, Alexander Gawlik, Martin Reinhardt, Silke Markau, Ralph Wendt, Anke Morgner, Anja Mühlfeld, Ana Harth, Saban Elitok, Wolfgang Miesbach, Jörg Radermacher, Johanna Schneider, Martin Hausberg, Charis von Auer, Martin Bommer, Markus Bieringer, Maximilian Roeder, Jörn Bramstedt, Frederic Bauer, Helmut Felten, Ulf Schoenermarck, Matthias Girndt, Hildegard Christ, Jessica Kaufeld, Anja Gäckler, Jens Gerth, Jens Gaedeke, Sebastian Brähler, Adrian Schreiber, Linus A. Völker, Marcus Brand, and Stefan Zschiedrich
- Subjects
medicine.medical_specialty ,Clinical Trials and Observations ,medicine.medical_treatment ,Medizin ,ADAMTS13 Protein ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Von Willebrand factor ,Fibrinolytic Agents ,Internal medicine ,hemic and lymphatic diseases ,von Willebrand Factor ,medicine ,Humans ,In patient ,Retrospective Studies ,Acquired Thrombotic Thrombocytopenic Purpura ,biology ,Purpura, Thrombotic Thrombocytopenic ,business.industry ,Immunosuppression ,Retrospective cohort study ,Hematology ,Single-Domain Antibodies ,ADAMTS13 ,Cardiovascular and Metabolic Diseases ,030220 oncology & carcinogenesis ,biology.protein ,Biomarker (medicine) ,Caplacizumab ,business - Abstract
Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was extended beyond day 30; and in 5 patients, it was extended even beyond day 58 due to persistent autoimmune activity. In 34 of 60 instances, caplacizumab was stopped before day 30 with a favorable outcome whenever ADAMTS13 activities were >10%. In contrast, 11 of 34 patients with ADAMTS13 activities
- Published
- 2020